Biotech and Pharma

Cash has flowed into oil stocks following the U.S.’s seizing of Venezuelan President Nicolás Maduro.

The company appears to have gotten the jump on Eli Lilly with what could be an important evolution in the market.

The company said it expects total revenue of between $450 million and $475 million this year, up from the $290 million to $310 million it had told investors to expect for 2025.

The biotech’s chief legal and financial officers were among four executives who sold shares on the same day.

Pill versions of GLP-1 drugs arrive in 2026, but analysts say Eli Lilly’s lead in obesity and diabetes treatment should hold for years.

The FDA cited insufficient evidence of effectiveness for relacorilant in patients with Cushing syndrome and hypertension, sending the stock sharply lower.

The FDA approved Vanda’s drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked to GLP-1 weight-loss drugs.

After getting thrashed by low-quality stocks in 2025, high-quality names should outperform in 2026.

An experimental treatment for an uncommon genetic bone disease failed in late-stage trials.

Nvidia and Tesla shares fall, DigitalBridge jumps after SoftBank agrees to acquire the data-center investment firm, and Newmont slumps as precious metals prices tumble.

Much in the new year depends on the fundamentals, which remain as complicated as ever. Watch these stocks.

At the current price, investors are paying little for Bristol Myers’ pipeline.

Nvidia is rising after reaching an agreement with AI start-up Groq, while Lam Research stock is on track for a record high.

The deal is likely an early Christmas gift for investors in Dynavax Technologies.

Novo Nordisk surges after U.S. regulators approve the first GLP-1 pill, while shares of rival pharma giant Eli Lilly decline.

Novo said it expects to launch the weight-loss pill in the U.S. in early January.

Vaxcyte keeps its place among Mizuho Securities top picks entering 2026.

Oracle shares jump following a joint venture agreement with TikTok, while Nike stock plummets following lackluster sales in China.

The growth potential of the weight-loss market could explode with advances, notably GLP-1 pills, and broader insurance coverage. That should change both health outcomes and the way Americas buy and consume food.

It’s the second acquisition for BioMarin in 2025, as the company seeks to diversify its product portfolio after the commercial failure of a hemophilia A gene therapy.

The Trump administration has talked tough on drug prices, but the impact of its deals with drugmakers so far has been limited.

Shares in memory-chip makers Micron and Sandisk rally after Micron tops Wall Street's earnings estimates.

Eli Lilly has a new pill, called orforglipron, it plans to launch next year.

The biopharmaceutical company said it was discontinuing development of a drug treating a chronic sinus condition.

Micron Earnings Impress Wall Street, Trump’s prediction of an economic boom may be wrong, more news to start your day.